Sugammadex vs Placebo to Prevent Residual Neuromuscular Block

• Status: Completed
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is designed to determine whether patients who receive sugammadex immediately after tracheal extubation will exhibit a decrease in the incidence of postoperative residual paralysis and an associated decrease in the incidence of postoperative respiratory depression.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mayo Clinic; The University of Texas Health Science Center, Houston
• Collaborators: Mayo Clinic; Merck Sharp & Dohme Corp.; Respiratory Motion, Inc.; University of Texas
• Treatments: Anesthetics

Criteria

Inclusion Criteria:

• Patients undergoing surgery with general anesthesia

• Patients weighing > or = 80 pounds

• Patients not intubated prior to surgery

• Patients who are able to give informed consent

Exclusion Criteria:

• Patients unable to give informed consent.

• Patients whose condition will not allow for placement of the electrode PadSet of ExSpiron

• Patients who are anticipated to remain intubated in recovery period.